Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07280156 | A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) | PHASE2 | RECRUITING | 150 | — | — | Dec 1, 2025 | Jun 1, 2028 | Feb 24, 2026 | - | — |
| NCT05745727 | A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels | PHASE1 | COMPLETED | 64 | — | — | Mar 1, 2023 | Feb 1, 2025 | Feb 10, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| PRX-115 | BIOLOGICAL | intravenous (IV) infusion |
| Methotrexate (MTX) | DRUG | Oral MTX 15 mg weekly |
| PRX-115 placebo | OTHER | intravenous (IV) infusion |
| Placebo-Methotrexate | OTHER | Oral Placebo-MTX weekly |
| Placebo | DRUG | Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8 |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| Protalix | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |